This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Neogen (NEOG) Q4 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Neogen (NEOG) Q4 fiscal 2023 results reflect core growth in both operating segments despite softening market conditions.
LabCorp (LH) Q2 Earnings Miss Estimates, Margins Decline
by Zacks Equity Research
A rise in organic revenues, acquisitions, net of divestitures and foreign currency translation drive LabCorp's (LH) Q2 revenues.
Edwards Lifesciences (EW) Q2 Earnings Top Estimates, View Up
by Zacks Equity Research
The growing adoption of the PASCAL Precision system in Europe and the United States and Edwards' premium products across all regions have driven Edwards Lifesciences' (EW) Q2 revenues.
Boston Scientific (BSX) Q2 Earnings Beat, Margins Improve
by Zacks Equity Research
Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the second quarter.
CONMED (CNMD) Beats on Q2 Earnings, Ups '23 EPS View
by Zacks Equity Research
CONMED's (CNMD) adjusted second-quarter earnings and sales recover from the disruption in the last two quarters due to implementation of a new warehouse management system.
Baxter (BAX) Beats on Q2 Earnings, Revises 2023 EPS Guidance
by Zacks Equity Research
Baxter's (BAX) second-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.
West Pharmaceutical (WST) Q2 Earnings Beat, HVP Drives Sales
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter results reflect a sustained recovery in non-COVID-19 demand amid dismal overall performance.
Fed's July Rate Hike and Comments Match Expectations: 5 Picks
by Nalak Das
We have narrowed our search to five U.S. corporate behemoths. These are: META, GOOGL, ISRG, JNJ, PEP.
Chemed (CHE) Q2 Earnings Miss Estimates, '23 EPS View Down
by Zacks Equity Research
Chemed's (CHE) second-quarter 2023 performance reflects strength in the VITAS segment, while expenses weigh on margins.
Align Technology (ALGN) Q2 Earnings Beat, Gross Margin Up
by Zacks Equity Research
Align Technology (ALGN) delivers impressive earnings in the second quarter of 2023.
Merit Medical (MMSI) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the second quarter.
Universal Health (UHS) Q2 Earnings Beat, Boosts '23 EPS View
by Zacks Equity Research
Universal Health's (UHS) Q2 results indicate improved patient admissions and solid segmental performance. Management currently expects adjusted EPS within $9.85-$10.50 for 2023.
Thermo Fisher (TMO) Q2 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Challenging macroeconomic conditions and slowdown in activities in China impede Thermo Fisher's (TMO) Q2 revenues.
Quest Diagnostics (DGX) Q2 Earnings Beat Estimates, FY View Up
by Zacks Equity Research
Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the second quarter of 2023.
Should First Trust NASDAQ-100 Equal Weighted ETF (QQEW) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQEW
NextGen (NXGN) Q1 Earnings Top Estimates, Revenues Surge Y/Y
by Zacks Equity Research
NextGen's (NXGN) first-quarter fiscal 2024 results reflect strength in its revenue sources.
Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Intuitive Surgical, Inc. (ISRG). This makes it worthwhile to examine what the stock has in store.
Top Analyst Reports for Alphabet, Procter & Gamble & Linde
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), The Procter & Gamble Company (PG) and Linde plc (LIN).
Intuitive Surgical (ISRG) Q2 Earnings Beat, Procedures Robust
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect healthy demand for procedures, partially offset by unfavorable currency. COVID-19 impacts procedure volume in China.
Intuitive Surgical, Inc. (ISRG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Intuitive Surgical, Inc. (ISRG) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Intuitive Surgical, Inc. (ISRG) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 7.58% and 1.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical (ISRG) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.
Is Intuitive Surgical (ISRG) A Buy Ahead of Q2 Earnings Announcement?
by Bryan Hayes
The established health care company has missed the earnings mark in two of the last four quarters.
2 Medical Stocks to Buy as Earnings Approach
by Shaun Pruitt
Among the broader healthcare space, Abbott Laboratories (ABT) and Intuitive Surgical (ISRG) are two medical stocks that will highlight this week's earnings lineup.
Intuitive Surgical (ISRG) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.